In critically ill patients with COVID-19, IL-6...

In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.

Abstract

SOURCE CITATION: Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.

Authors

Fuller C; Chagla Z

Journal

Annals of Internal Medicine, Vol. 176, No. 4,

Publisher

American College of Physicians

Publication Date

April 1, 2023

DOI

10.7326/j23-0020

ISSN

1056-8751

Associated Experts

Zain Chagla

Associate Professor, FHSMED

Visit profile

Labels

In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team